A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer by Muijs, Christina T. et al.
  
 University of Groningen
A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy
planning in patients with esophageal cancer
Muijs, Christina T.; Beukema, Jannet C.; Pruim, Jan; Mul, Veronique E.; Groen, Henk;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2010
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Muijs, C. T., Beukema, J. C., Pruim, J., Mul, V. E., Groen, H., Plukker, J. T., & Langendijk, J. A. (2010). A
systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients
with esophageal cancer. Radiotherapy and Oncology, 97(2), 165-171.
https://doi.org/10.1016/j.radonc.2010.04.024
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Radiotherapy and Oncology 97 (2010) 165–171Contents lists available at ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .comSystematic review
A systematic review on the role of FDG-PET/CT in tumour delineation
and radiotherapy planning in patients with esophageal cancer
Christina T. Muijs a,*, Jannet C. Beukema a, Jan Pruim b, Veronique E. Mul a, Henk Groen c, John Th. Plukker d,
Johannes A. Langendijk a
aDepartment of Radiation Oncology; bDepartment of Molecular Imaging and Nuclear Medicine; cDepartment of Epidemiology; and dDepartment of Surgery, University of
Groningen, The Netherlandsa r t i c l e i n f o
Article history:
Received 2 November 2009
Received in revised form 14 April 2010
Accepted 29 April 2010




Esophageal cancer0167-8140/$ - see front matter  2010 Elsevier Irelan
doi:10.1016/j.radonc.2010.04.024
* Corresponding author. Address: Department of Ra
Medical Center Groningen, University of Groningen
Groningen, The Netherlands.
E-mail address: c.t.muijs@rt.umcg.nl (C.T. Muijs).a b s t r a c t
Purpose: FDG-PET/CT has proven to be useful in the staging process of esophageal tumours. This review
analysed the role of FDG-PET/CT in tumour delineation and radiotherapy planning in comparison with CT
alone among patients with esophageal cancer. Thereby we focused on the detection of the primary
tumour and lymph nodes by FDG-PET/CT, changes in target volume (TV) delineation based on FDG-
PET/CT and its validity, changes in inter- and intra-observer variability in TV delineation, consequences
for radiotherapy treatment planning with regard to either target volumes or organs at risk and ﬁnally
on the validation of FDG-PET/CT-based TVs in terms of treatment outcome. Methods: A literature search
was performed in MEDLINE and Cochrane library databases for studies concerning the current value of
FDG-PET/CT in tumour detection and delineation and radiotherapy-planning procedures among patients
with esophageal cancer. Both prospective and retrospective studies were included. Results: Fifty publica-
tions met the eligibility criteria, of which 19 were review papers and one was a case report. The remain-
ing 30 publications reported on the results of original studies. FDG-PET was able to identify most primary
tumours, with a sensitivity and speciﬁcity for the detection of metastatic lymph nodes of 30–93% and 79–
100%. The use of FDG-PET/CT resulted in changes of target volumes, and consequently in changes in
treatment planning. However, evidence supporting the validity of the use of FDG-PET/CT in the tumour
delineation process is very limited. Only three studies reported a signiﬁcant positive correlation between
FDG-PET-based tumour lengths and pathological ﬁndings. There were two studies that tested the inﬂu-
ence of FDG-PET/CT to the inter- and intra-observer variability. One of them found a signiﬁcant decrease
in inter- and intra-observer variability, while the others did not. Furthermore, there are no studies dem-
onstrating the use of PET/CT in terms of improved locoregional control or survival. Conclusion: Since the
literature is very limited standard implementation of FDG-PET/CT into the tumour delineation process for
radiation treatment seems unjustiﬁed and needs further clinical validation ﬁrst.
 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 97 (2010) 165–171Esophageal cancer is the seventh leading cause of cancer-re-
lated death worldwide. In the last two decades, major efforts have
been made to improve locoregional tumour control and survival by
exploring new and emerging treatment strategies [34]. Treatment
of ﬁrst choice remains surgical resection. However, combined che-
mo-radiotherapy is increasingly applied, either as deﬁnitive ther-
apy or in the neo-adjuvant setting prior to a curatively intended
surgical resection [35].
Accurate delineation and subsequent irradiation of the gross
tumour volume (GTV) is a prerequisite for a successful treatment
of esophageal cancer with radiotherapy. This is particularly true
for the use of modern radiation (delivery) techniques, such asd Ltd. All rights reserved.
diation Oncology, University
, P.O. Box 30001, 9300 RBintensity-modulated radiotherapy (IMRT) or proton irradiation,
enabling a high level of radiation dose conformity and thus a high-
er risk of a lower dose than desired to the GTV in case of inade-
quate delineation.
Adequate tumour delineation for esophageal carcinoma is often
hampered by the poor discriminative value of currently used imag-
ing modalities, in particular computed tomography (CT), and the
inability to relate endoscopic (ultrasound) information to CT
images.
Addition of positron emission tomography (PET) information
may improve the accuracy in the delineation process. 18F-Fluoro-
2-deoxy-D-glucose (FDG) PET provides additional information on
the metabolic activity, i.e., glucose utilization of the tumour.
Tumour visualisation and thus tumour delineation may improve
by adding the functional information of FDG-PET to the anatomical
information of CT. Incorporation of FDG-PET, referred to as FDG-
PET/CT, in the delineation process seems to improve tumour
1 case report
114 potentially eligible papers, abstract form 
50 eligible papers, full text 
30 original studies 
19 review papers 
64 ineligible 
Fig. 1. The study selection process, both search strategies combined.
166 Role of FDG-PET/CT in esophageal tumour delineationcoverage and seems to spare normal tissues in various tumour
types, in particular in non-small cell lung cancer (NSCLC) [8,38].
Several studies showed that FDG-PET has been very useful in
the staging process of esophageal tumours [37]. FDG-PET is supe-
rior in detecting distant metastases and seems to improve nodal
staging as well, especially for non-adjacent lymph nodes. Further-
more, FDG-PET can be an effective tool for restaging esophageal
malignancies after (neo-adjuvant) treatment [41,42].
This review focuses on the additional value of FDG-PET/CT in
the tumour delineation process in comparison with CT alone
among patients with esophageal cancer. More speciﬁcally, the pur-
poses of this review were (1) to analyse the ability of FDG-PET(/CT)
to detect the primary tumour and/or pathologic lymph nodes; (2)
to determine if, and to what extent, the addition of FDG-PET
changes target volume delineation; (3) to assess the validity of
FDG-PET/CT with regard to GTV delineation; (4) to assess if the
addition of FDG-PET improves inter-observer and intra-observer
variability in target volume delineation; (5) to determine the con-
sequences for radiotherapy treatment planning with regard to
either target volumes or organs at risk, and ﬁnally; (6) to assess
the validation of FDG-PET/CT-based tumour delineation on treat-
ment outcome.Methods
Search strategy and selection criteria
A literature search was performed to retrieve articles concern-
ing the detection of esophageal tumours and pathologic lymph
nodes using the following keywords:
– synonyms for esophageal cancer
– synonyms for PET/CT
– synonyms for detection or synonyms for visualisation
These keywords were combined using ‘AND’. The search was
carried out in MEDLINE and Cochrane Library. In addition, refer-
ences lists of papers were screened in order to retrieve additional
relevant papers.
A similar search was performed for studies concerning the cur-
rent value of FDG-PET/CT in tumour delineation and radiotherapy-
planning procedures among patients with esophageal cancer. The
following keywords were used:
– synonyms for esophageal cancer
– synonyms for PET/CT
– synonyms for tumour delineation or synonyms for radiotherapy
To be selected for this review, studies had to fulﬁl the following
eligibility criteria: (1) squamous cell or adeno-carcinoma of the
esophagus or the gastro-esophageal junction; (2) eligible for cura-
tive treatment; (3) use FDG-PET in conjunction with CT; (4) FDG
used as a tracer in PET.
Both prospective and retrospective studies were included. Stud-
ies only available in abstract form were excluded from this review.
Articles in languages other than English were excluded as well.
The selection process of both search strategies together is sum-
marized in Fig. 1.Results
Literature search
Using the search strategies described, we were able to identify
114 publications. However, only 50 publications met the eligibility
criteria, of which 19 were review papers. In these papers, the use ofFDG-PET/CT in tumour staging process or in radiotherapy in gen-
eral was reviewed. One publication reported on a single case.
In the 30 studies, a total number of 1222 patients were in-
cluded. Table 1 summarizes the original studies concerning the
detection of esophageal cancer. Table 2 summarizes the original
studies concerning the tumour delineation process.
There were no studies available that provided level I or II evi-
dence for the beneﬁt of FDG-PET/CT vs. FDG-PET in the tumour
delineation process.
For reasons of clarity, the abbreviation FDG-PET/CT refers to
both software fusion-based PET added to CT and PET/CT images ac-
quired with an integrated PET/CT scanner.FDG-avidity of the primary tumour
Several studies have investigated the detection of the primary
tumour by FDG-PET. Increased uptake of FDG was seen in 68–
100% of the esophageal tumours (Table 1). Undetected tumours
are mostly stages T1 and T2 tumours. Especially T1a tumours,
remaining within the submucosa, are difﬁcult to detect by FDG-
PET [3,17].
Kato et al. [16] found a signiﬁcant relationship between the
intensity of the primary tumour FDG-uptake, expressed as SUV,
and the depth of the tumour invasion. However, Flamen et al.
[10] found no correlation between SUV and pT-stage.Detection of locoregional metastatic lymph nodes
The ability of different imaging modalities to identify metastatic
lymph nodes has been widely investigated. However, the literature
is not very consistent when it comes to the ability of CT, FDG-PET
or FDG-PET/CT to identify pathologic locoregional lymph nodes.
The sensitivity of CT and FDG-PET varied widely; 11–93% vs. 30–
93%. There was less variation regarding the speciﬁcity of CT and
FDG-PET; 71–100% vs. 79–100%, respectively (Table 1).
Recently, van Vliet et al. [36] published a meta-analysis on stag-
ing investigations for esophageal cancer. In this analysis, they
found a pooled sensitivity for the detection of regional lymph node
metastases by CT and FDG-PET of 0.50 (95% CI 0.41–0.60) and 0.57
(95% CI 0.43–0.70), respectively. The pooled speciﬁcity of CT was
0.83 (95% CI 0.77–0.89) vs. 0.85 (95% CI 0.76–0.95) for FDG-PET.
The pooled sensitivity of EUS was signiﬁcantly higher than both
CT and FDG-PET, but showed a similar diagnostic performance.
Four other studies evaluated the use of FDG-PET/CT for the
detection of locoregional lymph node metastases. Yuan et al. [46]
found a signiﬁcant improvement of the sensitivity (93%), accuracy
(92%) and negative predictive value (98%) in the assessment of
locoregional lymph nodes for esophageal cancer by the use of inte-
grated FDG-PET/CT, compared to the use of FDG-PET alone. Sihvo et
al. [33] also compared the ability of CT and FDG-PET to identify
metastatic lymph nodes to integrated FDG-PET/CT. In this study,
Table 1
Overview eligible original studies concerning the use of PET/CT for the detection of esophageal cancer.

























Pfau et al. [28] 44 80 92 – – – – – – 4 of 5 undetected
were T1–T2
Rankin et al. [29] 19 95 100 – – – – – –
Salahudeen et al.
[30]
25 – 100 – – – – – –
Wren et al. [43] 21 – – 71 86 57 71 – –
Kato et al. [17] 149 80 32 99 23 97 – – Most undetected were
T1
Kato et al. [16] 32 – 78 78 93 61 71 – – The not visible
tumours were T1
Flamen et al. [10] 39 95 33 89 0 100 – – All false negative on
PET were T1
Himeno et al. [13] 22 – 68 42 100 38 96 – – All undetected
tumours were T1
Block et al. [3] 58 – 94 52 79 29 79 – – 2 undetected lesions
were T1a
Kato et al. [15] 167 – 74 33 99 27 98 – – Most undetected were
T1–2
Kim et al. [18] 52 98 94 52 94 42 97 – – False negative on PET
was T1 tumour
Meltzer et al. [23] 47 97 87 35–41 90 63–87 14–43 – –
Yoon et al. [44] 79 82 92 30 90 11 95 – – All undetected
tumours were T1
Kole et al. [19] 26 81 96 92 88 38 100 – –
Sihvo et al. [33] 55 69 82 35 100 42 82 50 100 Of the false negative 7
T1 tumours and 3 T2
tumours
Yuan et al. [46] 45 – – 82 87 – – 94 92
Schreurs et al. [32] 85 – – – – – – 87 87
Table 2




Tumour delineation and radiotherapy




25 Separately P2.5 SUV The PET-tumour length was signiﬁcantly longer as measured by CT scans. PET-length correlated
better with endoscopy than with CT
Vrieze et al.
[40]
30 Separately – The irradiated volume should not be reduced based on negative PET ﬁndings, because of low
sensitivity. However, thanks to the high speciﬁcity it is possible to adapt the treatment volume
Hong et al. [14] 25 Integrated Visual/Pmean activity of
the liver + 2 SD
PET/CT appears to provide clinically meaningful data with a signiﬁcant impact on target deﬁnition




34 Fusion Visual PET/CT had impact on treatment planning. Impact on treatment outcome remains to be
demonstrated
Leong et al. [21] 16 Integrated SBR (liver activity)/visual PET/CT inﬂuences tumour delineation, with the potential to avoid geographic miss of tumour
Vesprini et al.
[39]
10 Integrated Visual PET/CT decreased the inter- and intra-observer variability identiﬁcation of the GTV
Schreurs et al.
[31]
28 Fusion SBR (liver activity)/visual Combining FDG-PET and CT may improve target volume deﬁnition with less geographic misses,
but without signiﬁcant effects on inter-observer variability in esophageal cancer
Muijs et al. [26] 21 Fusion SBR (liver activity)/visual TVs based on CT might exclude PET-avid disease. Consequences are under dosing. The addition of
PET in radiation planning might result in clinically important changes in NTCP
Comparison tumour length PET based vs. pathology
Mamede et al.
[22]
17 Integrated SBR (liver activity), different
SUV-thresholds




36 Integrated P2.5 SUV/40% SUVmax/
visual
The optimal PET method to estimate the length of gross tumour varies with tumour length and
SUVmax, an SUV cutoff of 2.5 seems best
Han et al. [12] 22 Integrated Visual/SUV-values for
autocontouring
A standardised uptake value cutoff of 2.5 on FDG-PET/CT provided the closest estimation of GTV
length
Yu et al. [45] 16 Integrated SBR (liver activity)/SUV-
values for autocontouring
The SUVbgd + 20% (SUVmax(slice)  SUVbgd) method optimally estimated gross tumour length, but
only reached an unsatisfactory CI for GTV
Abbreviations: GTV, gross target volume; SBR, source-to-background ratio; SUV, standard uptake value.
C.T. Muijs et al. / Radiotherapy and Oncology 97 (2010) 165–171 167the sensitivity was 42%, 35% and 50% for CT, FDG-PET and inte-
grated FDG-PET/CT, respectively. Although FDG-PET/CT improved
the sensitivity, it remained signiﬁcantly lower than that for EUS(p = 0.001). Both FDG-PET and FDG-PET/CT had a speciﬁcity of
100%, while CT showed a speciﬁcity of 82%. Schreurs et al. [32]
compared the detection of locoregional lymph node metastases
168 Role of FDG-PET/CT in esophageal tumour delineationon fused FDG-PET/CT to the detection of CT and FDG-PET side by
side in 18 patients. They found that the use of fused FDG-PET/CT
images improved the sensitivity (87% vs. 80%) and the speciﬁcity
(87% vs. 83%). Kato et al. [15] also evaluated the additional value
of PET/CT over PET for the detection of a metastatic lymph node
group. This study demonstrated that PET/CT had a higher sensitiv-
ity in lower thoracic regions than both PET and CT (p < 0.05).Target volume modiﬁcations
In nine studies, the use of FDG-PET/CT, based on either software
fusion [25,26,31,40] or integrated FDG-PET/CT [9,11,14,21,39], re-
sulted in changes of target volumes.
Gondi et al. found that the addition of FDG-PET resulted in GTV
reduction with more than 5% in 10 of 16 patients (62.5%). The
mean overlap between FDG-PET/CT- and CT-based GTVs was low,
only 46%. The observers delineated the GTVs independently.
Moureau-Zabotto et al. [25] evaluated the impact of the addi-
tion of FDG-PET to CT on GTV and PTV delineation among 34 pa-
tients treated with 3D-conformal radiotherapy. In this study, the
target volume was initially based on CT images. The corresponding
FDG-PET data were used as an overlay to the CT data to deﬁne the
GTV. This resulted in tumour length reduction in 12 patients (35%)
and an increase in 12 patients (35%). Modiﬁcations in GTV delinea-
tion resulted in a mean reduction of the GTV of 21.3% and a mean
increase of 20.0%. These changes in GTV affected the planning
target volume (PTV) in 18 patients (53%).
Leong et al. [21] also evaluated the impact of FDG-PET on CT-
based target volume delineation. They found an exclusion of
FDG-PET-avid disease in 11 of 16 patients (69%) when the GTV
was based on CT alone, with a median exclusion of FDG-PET/CT-
based GTV of 38%. In ﬁve patients (31%), the FDG-PET/CT-based
GTV was located outside the CT-based PTV, with a median exclu-
sion of 5%. Modiﬁcations based on FDG-PET/CT were mainly seen
in longitudinal direction.
Vrieze et al. [40] focused on the detection of pathologic lymph
node regions, instead of primary tumour extension and suggested
that the GTV should not be reduced based on negative FDG-PET
ﬁndings given the low sensitivity of FDG-PET in esophageal cancer.
Therefore, they stated that the GTV could only be enlarged based
on positive FDG-PET ﬁndings. In this study, the irradiated volume
was based on conventional imaging modalities, including CT and
endoscopic ultrasound (EUS). In 6 patients (20%), 8 pathologic
lymph node regions were detected on FDG-PET which were not
visible on conventional imaging. In three of these patients (10%)
this would have led to an increase of the CTV.
In most studies visual interpretation of FDG-PET images was
used for target volume delineation. Only a few studies used auto-
matic contouring, based on certain intensity levels, such as the
standard uptake value (SUV) level, a percentage of the maximal
SUV or the source-to-background ratio (SBR) [20,22,47].Pathological validation of FDG-PET ﬁndings
As described above, the addition of FDG-PET/CT resulted in
changes in the delineation of target volumes in a considerable pro-
portion of patients (20–94%). However, the question that remains
to be answered is whether these changes are justiﬁed. More specif-
ically, the question arises as to whether the FDG-PET/CT-based
changes correspond better with the actual pathological tumour
extension. The most ideal method to validate the additional value
of FDG-PET/CT would be to compare GTV delineations based on
different imaging modalities with the pathological specimens.
However, accurate validation is hampered by the difﬁculties in
obtaining pathological material and in comparing resected speci-mens with pre-surgical imaging. Therefore, reports on pathologic
validation are limited.
Mamede et al. [22] evaluated the correlation between tumour
length of esophageal carcinoma based on FDG-PET and pathological
data (n = 17). These tumour length measurements were taken from
fresh tissues obtained by surgical resections, without neo-adjuvant
treatment. They reported a signiﬁcant positive correlation between
FDG-PET-based tumour lengths, estimated for different SUV-
thresholds, and pathological ﬁndings. The best correlation was esti-
mated for a SUV-threshold of 2 – standard deviations (r = 0.74;
p < 0.001).
Similar results were found by Zhong et al. [47], comparing FDG-
PET-based tumour lengths with pathological specimens (n = 36). In
this study, three different methods were used to delineate the GTV:
(1) visual interpretation (LengthVis); (2) threshold at SUV 2.5
(Length2.5) and (3) threshold at SUV at 40% of the maximum
SUV (Length40). To correct for shrinkage of the surgical specimens,
the pathological tumour length was obtained by measuring the tu-
mour in situ before surgical removal. In addition, after surgical
resection, the specimen was longitudinally opened and stretched
to the same length as measured in vivo and pinned on a ﬂat board.
The FDG-PET-based tumour length correlated well with the patho-
logical tumour length, for all three thresholds (Lvis: r = 0.828; L2.5:
r = 0.887; L40: r = 0.857; p < 0.001). However, the tumour length at
a cutoff of SUV 2.5 seemed most approximate to the pathological
tumour length.
Recently, Han et al. [12] compared FLT-PET- and FDG-PET-based
tumour lengths with the tumour length in the pathologic specimen
of 22 patients. They found that for FDG-PET a SUV cutoff of 2.5 pro-
vided the closest estimation of GTV length.
Yu et al. [45] performed a similar study and compared FDG-PET-
based tumour lengths with the length of the gross tumour region
in vivo in 16 patients. They found no signiﬁcant difference in abso-
lute value between the CT-, PET- (SUVcutoff: SUVbackground + 20%)
and pathology-based tumour lengths. However, regarding the spa-
tial conformity index, the conformity index (CI) of pathology and
PETSUV+20% was signiﬁcantly superior to the CI obtained with
pathology and CT.
FDG-PET-based tumour lengths were also found to correlate
well with EUS-based tumour lengths [22], the gold standard for
clinical T-staging. Konski et al. [20] demonstrated that EUS-based
measurements of tumour length closely approximated FDG-PET-
based tumour measurements (n = 25), using a SUV-threshold for
malignancy of 2.5. The tumour length as determined by PET corre-
lated better with endoscopy than with CT and was signiﬁcantly
shorter as compared to those measured by CT, regardless of the
SUV. In this study, the CT-based tumour length was determined
on the CT part of the integrated FDG-PET/CT scan. The CT- and
FDG-PET-based tumour lengths were determined independently
by two different observers.Inter- and intra-observer variability
Another way to investigate the validity of new imaging tech-
niques in target volume delineation is to test inter- and intra-ob-
server variability, based on the assumption that lower inter- and
intra-observer variability represents more accurate delineation.
The effect of the addition of FDG-PET/CT on intra- and inter-ob-
server variability in target volume delineation in patients with gas-
tro-esophageal cancer was investigated in two studies. In the study
of Vesprini et al. [39], target volumes (n = 10) were delineated
based on CT and FDG-PET/CT in ten patients by six radiation oncol-
ogists. Combined use of FDG-PET/CT for delineation of the GTV sig-
niﬁcantly decreased both intra- and inter-observer variability. In
57% of the cases, observers felt more conﬁdent with the results
of GTV contouring.
C.T. Muijs et al. / Radiotherapy and Oncology 97 (2010) 165–171 169Schreurs et al. [31] also evaluated the effect of the additional
use of FDG-PET on the inter-observer variability in tumour volume
deﬁnition. For 28 patients the TVs were delineated by three
observers. In this study, they found no signiﬁcant effect on the in-
ter-observer variability.
For further reduction of the inter-observer variability, various
automatic or semi-automatic contouring methods were proposed.
However, usable SUV-thresholds, in order to distinguish pathologic
tissue from normal tissue, could not be determined [14,47].Consequences for radiotherapy planning and normal tissues
In only three studies, the consequences of FDG-PET-based tar-
get volume modiﬁcations on radiation dose distributions to target
volumes and organs at risk were analysed.
Leong et al. [21] reported 6 of 16 patients (38%) with inadequate
dose coverage (<95% receiving at least 95% of the prescribed dose)
of the FDG-PET/CT-based PTVs, if the treatment plans were based
on CT information alone. In these patients the percentage of the
FDG-PET/CT-based PTV, receiving at least 95% of the prescribed
dose, ranged from 63% to 92%. They found on average no clinically
signiﬁcant differences in radiation doses to the lungs, spinal cord
and liver between the CT and FDG-PET/CT-based treatment plans.
In contrast, Moureau-Zabotto et al. [25] found that FDG-PET/CT-
based changes in treatment plans resulted in changes in dose dis-
tribution to normal tissues in virtually all cases. The percentage of
total lung volume receiving >20 Gy (V20) was reduced after co-reg-
istration with FDG-PET-CT fusion in 12 patients with a mean
reduction of 29.1% ± 5% (range 5–69.8%). The V20 was increased
in 13 patients, with a mean increase of 25.3% ± 4% (range 3.4–
47%). As a result of the FDG-PET/CT-fusion, the percentage of total
heart volume receiving > 36 Gy increased in 11 patients (median
15.4%; range 0.3–103.3%), and decreased in 12 patients (median
21.8%; range 3.5–100%).
Recently, Muijs et al. [26] evaluated the consequences of the
additional use of FDG-PET for radiotherapy dose distribution for
esophageal cancer. They demonstrated that the use of CT-based
treatment plans may result in geographic mismatches and under
dosing of PET-avid disease. Furthermore, they showed that the
addition of PET led to signiﬁcant changes in dose distributions to
heart and lungs.Validation of the addition of PET by evaluating treatment outcome
parameters
The main clinical advantage of improved target volume delinea-
tion would be that the percentage of locoregional recurrences out-
side the delineated CTV reduces, eventually resulting in improved
locoregional control and subsequent overall survival. Therefore,
analysis of the localisation of locoregional recurrences reference
to the delineated target volumes and ultimate radiation dose dis-
tributions is of major importance. So far, there are no data available
on the evaluation of the use of FDG-PET/CT in the delineation pro-
cess for esophageal cancer by evaluating treatment outcome
parameters, as locoregional tumour control and survival.
Discussion
The results of this review showed that FDG-PET is able to detect
most esophageal tumours. Furthermore, FDG-PET/CT seems useful
for the detection of locoregional lymph nodes. The sensitivity and
speciﬁcity of FDG-PET/CT was better than of CT or PET alone.
We also showed that the use of FDG-PET/CT in target volume
delineation results in both reductions and increases of the GTV,
CTV and PTV in a considerable proportion of patients (Table 2).
Subsequently, these changes may result in both inadequate dosecoverage of the PTV and, in some cases, even of the CTV and
GTV, and in clinically relevant changes in dose distributions to nor-
mal tissues [11,21,25].
There is no doubt that GTV delineation is affected by the diag-
nostic information used. In clinical practice, all available informa-
tion, such as physical examination, endoscopy reports, EUS and
diagnostic contrast-enhanced CT scans, is applied for delineation
of the target volume. In most of the reviewed studies, this informa-
tion was available for both CT- and FDG-PET/CT-based GTV delin-
eation [11,14,21,39]. However, in other studies, this information,
which we consider essential, was disregarded and the delineation
of the GTVs was exclusively based on CT- or FDG-PET/CT-informa-
tion [20,25,40]. This implies that the results of these latter studies
may be less representative for use in clinical practice.
The clinical use of FDG-PET/CT may also be hampered by some
technical issues. For FDG-PET/CT-based GTVs, two types of con-
touring methods were used, including visual interpretation (with
or without source-to-background correction), or semi-automatic
contouring based on different SUV-thresholds. However, these
methods are neither objective nor uniform. For visual interpreta-
tion, which is the main tool used in clinical practice and used in
most of the reviewed studies, image representation can be con-
trolled by changing window-widths and window-levels, which is
highly observer dependent, and may result in signiﬁcant differ-
ences in visible tumour volumes. The SUV is, on the other hand,
a semi-quantitative parameter for evaluation of the FDG-uptake
in tumours. However, many factors, such as patient preparation
procedures, scan acquisition, image reconstruction and data analy-
sis settings, affect the outcome of the SUV [5,6]. Even though these
factors have small effects individually, accumulation of many of
these factors can result in considerable differences in SUV outcome
[4]. For this reason, recommendations for standardisation and
quantiﬁcation of FDG-PET studies have been made by Boellaard
et al. [4,6]. In the currently available literature, SUV-thresholds to
distinguish pathological tissues from normal tissues could not be
determined for esophageal cancer. For other tumours, for example,
NSCLC, estimation of a reliable automatic contouring method re-
mains difﬁcult as well [27].
The way in which additional FDG-PET information is incorpo-
rated in the tumour delineation process will also inﬂuence the
changes in target volume. In the reviewed studies, two main
methods (Table 3) were used: (1) delineation of the CT-based
GTV and modiﬁcation of this target volume based on the additional
PET information; (2) independent delineation of CT- and PET/
CT-GTVs. Using the latter method, target volume modiﬁcations
could partially be explained by intra-observer variability. On the
other hand, observers using the ﬁrst method are more prejudiced
by their CT ﬁndings. The lack of uniformity in the methods, by
which FDG-PET information has been used to contour the GTV,
illustrates the difﬁculty to incorporate FDG-PET information prop-
erly into the tumour delineation process.
Another shortcoming is the use of co-registered FDG-PET/CT
images for tumour delineation. Software-based co-registration
seems less accurate, considering the errors associated with this
type of image co-registration. To minimize these errors, all FDG-
PET- and CT-scans, used in the reviewed studies, were made in
treatment position.
Despite the non-standardised way of the use of FDG-PET for tu-
mour delineation, which might result in an over or under estima-
tion of the GTV modiﬁcations, these changes may have an effect
on treatment outcome in terms of both the locoregional tumour
control and the incidence of radiation-induced side effects.
It is clear that the main advantage of FDG-PET/CT in the man-
agement of esophageal cancer is the higher validity with regard
to lymph node status and the detection of occult metastases. Inte-
grated FDG-PET/CT has overall a higher sensitivity, speciﬁcity and
Table 3
Changes in target volume by addition of PET(/CT) in tumour delineation process.







Proportion Proportion Size Proportion Size
Vrieze et al. [40] 20 (6/30) 10 (3/30) Not deﬁned 10 (3/30) Not deﬁned CTV Not described I Fusion
Gondi et al. [11] 94 (15/16) 31 (5/16) Not deﬁned 62.5 (10/
16)
>5% GTV SBR (liver activity)/
visual
II Integrated
Hong et al. [14] 84 (21/25) – D sup/inf
extent > 1 cm
– D sup/inf






56 (19/34) 21 (7/34) 20% ± 8.7 35 (12/34) 21.3% ± 4.7 GTV Visual I Fusion
53 (18/34) 21 (7/34) 22% ± 11 33 (11/34) 9.8% ± 7.4 PTV2
Leong et al. [21] >69 (11/
16)
– Not deﬁned – Not deﬁned GTV SBR (liver activity)/
visual
II Integrated
Muijs et al. [26] 76 (16/21) 24 (5/21) >3 mm 52 (11/21) >3 mm GTV SBR (liver activity)/
visual
II Integrated
Abbreviations: TV, target volume; GTV, gross tumour volume; CTV, clinical target volume; PTV, planning target volume; SBR, source-to-background ratio.
Contour method: I, CT-delineations were modiﬁed based on PET/CT images; II, CT- and PET/CT-GTVs were delineated separately and blinded.
170 Role of FDG-PET/CT in esophageal tumour delineationaccuracy compared to CT or FDG-PET alone [1,2]. In this respect,
the addition of FDG-PET/CT will certainly have an impact on treat-
ment strategies, e.g., in deciding about the intent of treatment (e.g.,
in case of detection of distant metastases) and in assessing radio-
therapy target volume deﬁnition (e.g., in case of detection of path-
ological lymph nodes). However, one of the questions that still
remains to be answered is whether the FDG-PET/CT-based GTV
corresponds better with the pathological tumour than CT-based
GTV.
FDG-PET-based tumour lengths correlate well with tumour
lengths as assessed by pathologic examination or EUS. However,
tumour length correlation does not automatically mean correct
tumour imaging in terms of tumour localisation. It is not unlikely
that low FDG-uptake in pathologic areas on one side is compensated
on the other side by, for example, false-positive uptake in areas of
inﬂammation. It is well known that areas surrounding the tumour
can become inﬂammatory, and FDG-PET frequently shows false-
positive uptake in areas of inﬂammation [24]. Therefore, the
available data published so far do not provide sufﬁcient evidence
that the FDG-PET/CT-based changes in the GTV represent better
pathological tumour coverage than CT-based GTV delineation.
Ultimately, the use of FDG-PET/CT for GTV delineation for radio-
therapy treatment-planning purposes should be validated based
on treatment outcome parameters, such as locoregional control
and survival. However, as to our knowledge, no such studies, eval-
uating the use of FDG-PET/CT in the radiotherapy process for
esophageal cancer, have been carried out.
We were able to retrieve only one study in which recurrence
analysis was performed after irradiation with the use of CT and
EUS-based 3D-conformal radiation treatment plans [7]. In this
study, 55 of 85 relapses (65%) were local recurrences that were lo-
cated within the PTV. Only 3 patients (4%) developed regional
recurrences outside the PTV, which theoretically could have been
prevented by improved GTV delineation, e.g., by the additional
use of PET. These results suggest that the target volumes were ade-
quately deﬁned based on CT/EUS in the fast majority of cases. In
this study, localisation of the relapses were considered in relation
to the PTV (within or outside the PTV). However, margins to the
PTV are deﬁned to compensate for set up uncertainties to assure
adequate dose coverage of the clinical target volume (CTV). Varia-
tions in daily positioning of the patient are unavoidable, despite
measures to ensure a high reproducibility and accuracy. Further-
more, intrafractional tumour motion within the patient occurs
due to cardiac action and respiration. Therefore, the actual dose
delivered to the PTV itself will be less than the prescribed dose,
depending on the size and type (random or systematic) of the setup deviations. Based on the results of this study we cannot con-
clude that CT-based treatment plans were adequate or not.
The increasing use of more advanced and emerging radiation
delivery techniques, generally resulting in higher conformality of
the required radiation dose to the target volume, requires more
accurate imaging tools for accurate delineation of the GTV in order
to prevent geographical misses. In this respect, additional tools to
identify pathological tumour are of great importance. However, the
current review shows that the available data do not provide sufﬁ-
cient evidence that the integration of FDG-PET/CT will necessarily
improve the accuracy of GTV delineation and, eventually, subse-
quent locoregional tumour control.
Currently, a prospective multicenter study (RESPECT-study) is
running in the Netherlands aiming to determine the proportion
of patients with a locoregional recurrence after CT-based radio-
therapy or chemoradiation that can be considered preventable
when PET/CT-based treatment planning was used instead of CT-
based treatment planning alone. In this study, pre-treatment
FDG-PET/CTs are made for planning as well as CTs during follow
up. In case of tumour recurrence, FDG-PET/CT is made to localise
the recurrence in relation to the CT- and PET/CT-based CTVs.
Conclusion
FDG-PET is able to detect most esophageal tumours and seems
useful for the detection of locoregional lymph nodes. However, evi-
dence supporting the use of FDG-PET/CT in the tumour delineation
process and radiotherapy planning is very limited. Tumour length
comparison as pathological validation has important shortcomings
and seems therefore unreliable. Furthermore, there are no studies
demonstrating the use of PET/CT in terms of improved locoregional
control or survival. Standard implementation of FDG-PET/CT into
the tumour delineation process for radiation treatment seems
therefore unjustiﬁed at this moment and needs further clinical val-
idation ﬁrst. This is now subject of a prospective multicenter study
in the Netherlands.
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